Lexicon Pharmaceuticals, Inc.
LXRX
$0.5316
-$0.0003-0.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.77M | -64.81M | -53.43M | -48.40M | -49.76M |
| Total Depreciation and Amortization | 125.00K | 126.00K | 139.00K | 144.00K | 147.00K |
| Total Amortization of Deferred Charges | 401.00K | 402.00K | 525.00K | 517.00K | 618.00K |
| Total Other Non-Cash Items | -19.00K | 974.00K | -25.00K | 4.08M | 2.72M |
| Change in Net Operating Assets | 11.77M | 9.69M | 4.25M | -11.47M | -4.28M |
| Cash from Operations | -21.49M | -53.62M | -48.54M | -55.13M | -50.55M |
| Capital Expenditure | -474.00K | -307.00K | -250.00K | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.17M | 53.78M | -12.07M | -110.22M | 51.90M |
| Cash from Investing | 53.70M | 53.47M | -12.32M | -110.22M | 51.90M |
| Total Debt Issued | -- | -- | -- | -- | -1.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 1.00K | 88.00K | 0.00 |
| Repurchase of Common Stock | -25.00K | 0.00 | 0.00 | -1.73M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | 241.43M | -- |
| Repurchase of Preferred Stock | -78.00K | -10.00K | -15.00K | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00K | -906.00K | 0.00 | -400.00K | -- |
| Cash from Financing | -104.00K | -916.00K | -14.00K | 239.38M | -1.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.11M | -1.07M | -60.88M | 74.03M | 1.35M |